# The 'Safer' Switch That Made It Worse Prescribing Decision — Hypertension 34 # The 'Safer' Switch That Made It Worse Why the non-stimulant label does not mean what it sounds like ## Presentation A **34-year-old woman with ADHD** has taken **lisdexamfetamine 50 mg daily** for four years with good symptom control. At a routine visit her blood pressure is **montage-confirmed 148/94** on repeat readings, and home monitoring confirms stage 1 hypertension. She has CKD stage 2 from reflux nephropathy. Concerned about the stimulant, her psychiatrist switches her to **atomoxetine 80 mg daily**, explaining that a non-stimulant will be safer for her blood pressure. ### Six weeks later Home blood pressure is **unchanged to slightly higher**, resting heart rate has risen from 76 to 88, and her ADHD symptoms have worsened. She asks whether the switch was worth it. ## Questions 1 #### Was the reasoning behind the switch pharmacologically sound? A\) Yes — non-stimulants reliably have less cardiovascular effect B) No — atomoxetine is a pure norepinephrine transporter inhibitor C) Yes, but the dose chosen was too high D) No — atomoxetine should have been combined with the stimulant **Correct Answer: B**\ **Learning Point:** **Atomoxetine is a selective NET inhibitor** — blocking norepinephrine reuptake is precisely the mechanism that raises blood pressure and heart rate. In a network meta-analysis of 102 trials, amphetamines, lisdexamfetamine, and methylphenidate were **not** associated with larger haemodynamic increments than atomoxetine or viloxazine, and **atomoxetine produced the largest pulse increase of any agent studied in children (+5.58 bpm)**. The category name describes the abuse-liability profile, not the haemodynamics.\ **📚 Reference:** [Lecture: Psychiatric & ADHD Medications and Blood Pressure](https://urinenephrology.org/2025_UDPA_Lectures_Live/psychotropic-blood-pressure/index.html) 2 #### Which ADHD medication would be expected to LOWER her blood pressure? A\) Viloxazine B) Methylphenidate C) Guanfacine extended-release D) Modafinil **Correct Answer: C**\ **Learning Point:** **Guanfacine is an alpha-2 agonist** — a licensed antihypertensive that also treats ADHD. In the same network meta-analysis it produced decrements in every haemodynamic parameter, with a mean adult systolic decrease of about **10 mmHg** versus placebo. Viloxazine is another NET inhibitor and behaves like atomoxetine.\ **📚 Reference:** [Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD](https://urinenephrology.org/mastery/hypertension-advanced/psychotropic-adhd-medications-blood-pressure.html) — Section 4.3 3 #### If guanfacine is started, what must be actively managed? A\) Her potassium, because alpha-2 agonists cause hyperkalemia B) Her other antihypertensives may need to be reduced, and she should be watched for bradycardia and postural dizziness C) Her lisdexamfetamine must be tapered over 6 months first D) Nothing — guanfacine has no cardiovascular monitoring requirements **Correct Answer: B**\ **Learning Point:** The two-birds prescription has a trap. In long-term adult use, **decreased blood pressure, postural dizziness, and bradycardia were among the commonly reported adverse events**. If guanfacine is started in a patient already on antihypertensives, **the regimen may need to come down, not up** — and this requires coordination with psychiatry rather than parallel prescribing.\ **📚 Reference:** [Student Handout](https://urinenephrology.org/student-resources/pharmacology/psychotropic-adhd-medications-student-handout.html) — Section 4 4 #### Her CKD is stage 2 now but may progress. Which statement about guanfacine in advanced kidney disease is correct? A\) It requires 50% dose reduction below eGFR 30 B) It is contraindicated in dialysis C) No major dose adjustment is needed — non-renal elimination compensates D) It must be dosed only after dialysis sessions **Correct Answer: C**\ **Learning Point:** Across the GFR spectrum, guanfacine's **renal clearance collapses more than tenfold** (233 → 34 → 18 mL/min) and urinary excretion falls from 57% to 7.5% — yet **total body clearance is largely preserved and the elimination half-life stays at 14 hours independent of renal function**, because non-renal elimination takes over. Note the wide variability in these small studies: 'no major adjustment' means start low and titrate, not that monitoring is unnecessary.\ **📚 Reference:** [Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD](https://urinenephrology.org/mastery/hypertension-advanced/psychotropic-adhd-medications-blood-pressure.html) — Section 7.3 5 #### She asks whether staying on a stimulant long-term would have damaged her heart. What is the most accurate answer? A\) Yes — stimulants clearly increase heart attack and stroke risk B) No hard-event excess has been shown, but long-term use is associated with developing hypertension C) There is no evidence of any cardiovascular effect whatsoever D) Risk applies only to patients over 65 **Correct Answer: B**\ **Learning Point:** Two very large cohorts (1.2 million children and young adults; 150,000 adults) found **no increase in myocardial infarction, stroke, or sudden death**. But a case-control study of 278,027 people found the risk of **incident hypertension rose with cumulative duration — about 1.8-fold beyond 5 years**. These do not conflict: a drug adding roughly 2 mmHg and 4 bpm will not rupture a plaque this year, but it shifts the pressure distribution over a decade. For a patient with CKD, that slow shift is the outcome that matters most.\ **📚 Reference:** [Clinical Mastery: Psychotropic and ADHD Medications in Hypertension and CKD](https://urinenephrology.org/mastery/hypertension-advanced/psychotropic-adhd-medications-blood-pressure.html) — Section 4.4 ## Take-Home ### Choose by mechanism, not by category “Stimulant” versus “non-stimulant” is a **regulatory and abuse-liability distinction, not a haemodynamic one**. The question that predicts blood pressure is always the same: **does this drug block norepinephrine reuptake?** Atomoxetine and viloxazine do. Guanfacine and clonidine do the opposite. **What the evidence cannot tell you:** there are **no studies of ADHD medications in CKD or dialysis populations**. Every renal recommendation in this area is inferred from elimination pathways. Say so when you counsel the patient — an acknowledged gap is more useful than a confident number you cannot source. **Andrew Bland, MD, FACP, FAAP** Medical Associates Department of Nephrology · University of Illinois College of Medicine at Peoria · University of Dubuque PA & DPT Programs · Butler College of Osteopathic Medicine *Interactive teaching case · Psychotropic & ADHD Medications and Blood Pressure* © 2026 · [urinenephrology.org](https://urinenephrology.org) --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case34_atomoxetine_guanfacine_adhd_htn.html) · Markdown synchronized October 3, 2026.